RN Mobile Menu

Search form





An increased risk of cardiovascular disease is present in early rheumatoid arthritis and early spondyloarthritis, new research shows.

Improvements were seen in some patients participating in a phase 3 clinical trial as quickly as 4 weeks after the first treatment.

 ©Susie Prentice/shutterstock.com

Patients with psoriatic arthritis achieve significant improvements in signs and symptoms with the interleukin-12/23 inhibitor ustekinumab (Stelara), and they maintain those gains for 2 years, according to final results from 3 major clinical trials.

©Left-Handed Photography/Shutterstock.com

A rheumatologist picks 5 studies he found particularly noteworthy at EULAR and gets right to the point about their potential clinical implications.


The first study to assess the effects of DMARDs or anti-TNF treatment in a real world population of patients with inflammatory arthritis shows a clinically significant improvement in work disability, productivity loss, and disease activity-- especially in those receiving TNF-α blockers.


Many patients with ankylosing spondylitis have aortic regurgitation: this study makes the case for routine echocardiography evaluation.


Only 1% to 3% of patients with non-radiographic axial spondyloarthritis achieve remission or low disease activity without TNF-α blockers, but these agents are not yet approved for this use in the US.


Subscribe to Spondyloarthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.